Africa Anti-Depressants Drugs Market Report 2022 to 2030

Africa Anti-Depressants Drugs Market Analysis

$ 3999

African Anti-depressant drugs market size was valued at $16.44Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 5.90% from 2022-30 and will reach $26 Bn in 2030. The market is segmented by drug class, indication, route of administration, end-user, and distribution channel. The African anti-depressant drug market will grow because of The rising prevalence of depression across the region. The key market players are GlaxoSmithKline plc (GBR), AstraZeneca (GBR), Mallinckrodt (GBR), Novartis AG and others.

ID: IN10AFPH051 CATEGORY: Pharmaceuticals GEOGRAPHY: Africa AUTHOR: Chandani Patel

Buy Now

Africa Anti-Depressants Drugs Market Executive Summary

African Anti-depressant drugs market size was valued at $16.44Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 5.90% from 2022-30 and will reach $26 Bn in 2030. Mental health expenditure in Africa varies widely from country to country, and overall, it is generally lower than in other parts of the world. According to a 2020 report by the World Health Organization (WHO), the average mental health expenditure per capita in Africa was $0.18, which is significantly lower than the global average of $3.84 Bn. In many African countries, mental health is often not given the same priority as physical health, and resources are limited. This can result in a lack of access to essential mental health services, such as counseling, medication, and specialized care. There is also often a shortage of mental health professionals, particularly in rural areas. Some countries in Africa have taken steps to increase their mental health expenditure and improve mental health services. In South Africa, the government has increased mental health spending in recent years and has also launched a national mental health policy to improve services.

Depression is a significant public health problem in Africa, but the prevalence of the condition varies from country to country. According to a 2019 study published in the journal BMC Psychiatry, the prevalence of major depressive disorder in Africa ranges from 1.4% to 9.6%, with a median prevalence of 3.3%. This is similar to the global prevalence of depression, which is estimated to be around 4.4%. There are several factors that contribute to the high prevalence of depression in Africa. These include poverty, political instability, conflict, and social inequalities. Additionally, the high burden of infectious diseases, such as HIV/AIDS and malaria, can also increase the risk of depression.

According to a 2019 study published in the journal BMC Psychiatry, the prevalence of antidepressant uses in Africa ranges from less than 1% to 2.7%, which is much lower than the global average of 6.8%. There are several reasons why antidepressant use is relatively low in Africa. One reason is the limited availability of these medications in many countries, particularly in rural areas. Additionally, there is often a lack of awareness and understanding about mental health and depression, which can lead to underdiagnosis and undertreatment. However, there are efforts underway to improve access to mental health services and increase the use of antidepressant drugs in Africa. For example, the World Health Organization has launched a mental health gap action program to improve access to evidence-based mental health services in low- and middle-income countries, including many African countries. Additionally, some African countries, such as South Africa, have developed national mental health policies that prioritize the integration of mental health services into primary care and the expansion of mental health services in the public sector. Therefore, the demand for anti-depressants drugs will increase in coming years.

africa anti depressent drugs market

Market Dynamics

Market Growth Drivers

Increasing prevalence of depression: The rising prevalence of depression globally is a significant driver of the antidepressant drugs market. As more people are diagnosed with depression, there is a growing demand for antidepressant medications.
Growing awareness and acceptance of mental health: The increasing awareness and acceptance of mental health issues and the importance of seeking treatment for these conditions are driving demand for antidepressant drugs.
Advancements in drug development: The development of new and more effective antidepressant drugs is driving growth in the market. Pharmaceutical companies are investing heavily in research and development to create new drugs with fewer side effects and better efficacy.

Market Restraints

Side effects of antidepressant drugs: Antidepressant drugs can cause several side effects, such as nausea, insomnia, and sexual dysfunction. This can limit patient compliance and contribute to lower demand for these drugs.
High cost of medication: The high cost of antidepressant drugs can limit access to treatment for people who cannot afford these medications, particularly in low- and middle-income countries.
Stigma and negative perceptions of antidepressant drugs: Stigma surrounding mental illness and negative perceptions of antidepressant drugs can limit patient acceptance and contribute to lower demand for these medications.

Competitive Landscape

Key Players

Aspen Pharmacare
Hikma Pharmaceuticals
Adwia Pharmaceuticals
Biogaran
Pharco Pharmaceuticals
Bausch Health Companies Inc.
Lundbeck
Purdue Pharma
Takeda Pharmaceutical
AbbVie Inc.
Mylan N.V.
Novartis AG

Healthcare Policies and Regulatory Landscape

Regulations for antidepressant drugs in Africa vary by country, and there is no single regulatory body that governs drug approval and distribution across the continent. Each country has its own regulatory agency responsible for drug approval and monitoring. In some African countries, antidepressant drugs are classified as prescription-only medications, and they can only be dispensed by a licensed healthcare provider. In other countries, these medications may be available over the counter without a prescription.

Many African countries rely on the World Health Organization (WHO) guidelines for drug regulation and approval. The WHO provides guidance on the quality, safety, and efficacy of medications, including antidepressants, and works with national regulatory agencies to ensure that these standards are met. However, regulatory oversight of antidepressant drugs in Africa can be limited by several factors, including limited resources, staffing, and infrastructure. Some countries may also have weak regulatory frameworks or may be prone to corruption, which can compromise the safety and effectiveness of medications.

Despite these challenges, efforts are underway to strengthen regulatory oversight of antidepressant drugs in Africa. The African Medicines Regulatory Harmonization (AMRH) initiative, for instance, it is a regional effort to improve regulatory capacity and harmonize drug approval processes across the continent. Additionally, some African countries have developed national regulatory frameworks for drugs and established regulatory agencies to oversee drug approval and distribution.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Anti-Depressants Drugs Market Segmentation

Drug Class

The market is divided into monoamine oxidase inhibitors, atypical antidepressants, tricyclic, serotonin, and norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, and others based on pharmacological class. In 2021, the selective serotonin reuptake inhibitors (SSRIs) market segment held the biggest market share. The strength of the pipeline of top players to assess new potential candidates in this drug class, combined with the clinical advantage of SSRIs over conventional medications in the management and treatment of depression, is anticipated to accelerate the segment's growth.

Tricyclic Antidepressants (TCAs) - Amitriptyline (Elavil), Amoxapine (Asendin), Desipramine (Norpramin), Doxepin (Silenor), Imipramine (Tofranil), Nortriptyline (Pamelor), Protriptyline (Vivactil), Trimipramine (Surmontil)
Selective Serotonin Reuptake Inhibitors (SSRIs) - Citalopram (Cipramil), Dapoxetine (Priligy), Escitalopram (Cipralex), Fluoxetine (Prozac or Oxactin), Fluvoxamine (Faverin), Paroxetine (Seroxat), Sertraline (Lustral), Vortioxetine (Brintellix)
Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) - Desvenlafaxine (Pristiq), Duloxetine (Cymbalta), Levomilnacipran (Fetzima), Venlafaxine (Effexor XR)
Monoamine Oxidase Inhibitors (MAOIs) - Socarboxazid (Marplan), Phenelzine (Nardil), Selegiline (Emsam), Tranylcypromine (Parnate)
Serotonin Antagonist and Reuptake Inhibitors (SARI) - Etoperidone (Axiomin, Etonin), Lorpiprazole (Normarex), Mepiprazole (Psigodal), Nefazodone (Serzone, Nefadar), Trazodone (Desyrel)
Others

Indication

By Indication, the major depressive disorder segment was the major contributor in 2021 and is expected to maintain its lead during the forecast period, owing to an increase in the prevalence of major depressive disorder and initiatives taken by governments and private organizations about the development of drugs. However, the obsessive-compulsive disorder segment is expected to witness considerable growth during the forecast period, owing to an increase in the prevalence of mental disorders and an increase in the number of approval for anxiety drugs.

Major Depressive Disorder
Anxiety Disorders
Attention Deficit Hyperactivity Disorder
Others

Route of Administration

Based on the route of administration the market is segmented into:

Oral
Injectable
Others

End-Users

Based on end users the market is segmented into:

Hospitals
Homecare
Speciality Centres
Others

Distribution Channel

Hospital pharmacies, retail pharmacies, and online pharmacies are the three types of pharmacies that make up the market based on the distribution channel. In 2019, the hospital pharmacies segment dominated the world market. Nonetheless, the expansion of the retail pharmacy market might be attributed to patients' increasing demand for these establishments. Due to the growing prevalence of online pharmacies in emerging countries, the segment of online pharmacies is estimated to see a profitable CAGR over the forecast timeframe.

Hospital Pharmacy
Online Pharmacy
Retail Pharmacy

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.